Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

AbbVie Inc., solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An analysis of solvency metrics reveals a period of relative stability followed by an exponential increase in leverage and a significant deterioration of the equity cushion between March 2022 and March 2026.

Debt to Equity Ratio
The ratio remained within a range of 3.67 to 5.73 from March 2022 through December 2023. A sharp upward trajectory commenced in March 2024, with the value escalating to 20.19 by December 31, 2024, and reaching a peak of 49.22 by March 31, 2025. This trend indicates a severe reduction in shareholder equity relative to total debt.
Debt to Capital Ratio
A consistent and steady increase is observed, rising from 0.82 in early 2022 to 1.10 by March 2026. The ratio surpassed the 1.00 threshold in June 2025, signifying that total debt exceeds the combined total of debt and equity, a condition typically associated with negative equity.
Debt to Assets Ratio
This metric exhibits the highest degree of stability among the solvency ratios, fluctuating within a narrow band between 0.44 and 0.53. After a slight decline during 2022 and 2023, the ratio stabilized around 0.50 throughout 2024 and 2025, ending at 0.53 in March 2026. This suggests that while leverage increased, the proportion of assets financed by debt remained relatively constant at approximately 50%.
Financial Leverage
Financial leverage followed a trajectory similar to the debt-to-equity ratio. After moderate growth from 8.80 in March 2022 to 13.00 in December 2023, a period of extreme escalation occurred. The ratio climbed from 18.59 in March 2024 to 95.89 by March 31, 2025, reflecting a highly aggressive increase in the use of debt to support the asset base.

The correlation between the explosive growth in financial leverage and the debt-to-equity ratio, contrasted with the relative stability of the debt-to-assets ratio, suggests a substantial erosion of the equity base rather than a proportional increase in total assets. By early 2026, the solvency profile indicates a heavily leveraged capital structure with negative equity.


Debt Ratios


Debt to Equity

AbbVie Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Stockholders’ equity (deficit)
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= ÷ =

2 Click competitor name to see calculations.


An analysis of the solvency metrics reveals a significant deterioration in the financial leverage position over the observed period. While total debt remained relatively stable within a specific range, a continuous and accelerating decline in stockholders' equity led to an exponential increase in the debt-to-equity ratio, culminating in a negative equity position.

Total Debt Trends
Total debt exhibited a period of gradual decline throughout 2022 and 2023, reaching a low of 59,385 million US dollars by December 31, 2023. A sharp increase occurred in the first quarter of 2024, with debt rising to 74,001 million US dollars. Following this peak, the balance fluctuated between approximately 67,000 million and 72,000 million US dollars through March 31, 2026.
Stockholders' Equity Erosion
A persistent downward trend in stockholders' equity is observed, starting from 16,283 million US dollars in March 2022. This balance declined steadily through 2023 and 2024, dropping to 3,325 million US dollars by December 31, 2024. The equity position further eroded until it transitioned into a deficit in June 2025, continuing to widen to a negative balance of 6,656 million US dollars by March 31, 2026.
Debt to Equity Ratio Progression
The debt-to-equity ratio reflects the compounding effect of stable debt levels against a shrinking equity base. Between March 2022 and December 2023, the ratio remained relatively contained, fluctuating between 3.67 and 5.73. However, a critical escalation began in 2024, with the ratio rising from 9.24 in March to 20.19 by December. By March 31, 2025, the ratio reached 49.22, immediately preceding the shift to negative equity, at which point the ratio became mathematically non-representative of standard solvency.

Debt to Capital

AbbVie Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Stockholders’ equity (deficit)
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


An analysis of the solvency metrics from March 31, 2022, to March 31, 2026, reveals a significant shift in the capital structure, characterized by a steady increase in leverage over the latter half of the period.

Debt to Capital Trend
The debt to capital ratio remained relatively stable between March 2022 and December 2023, fluctuating within a narrow range of 0.79 to 0.85. However, beginning in March 2024, a consistent upward trajectory is observed. The ratio rose from 0.90 in March 2024 to 1.10 by March 2026. A critical threshold was crossed in June 2025, when the ratio reached 1.00, indicating that total debt equaled total capital, subsequently exceeding it in the following quarters.
Total Debt Dynamics
Total debt exhibited a period of gradual reduction from March 2022, decreasing from 73,474 million USD to a low of 59,385 million USD by December 2023. This trend reversed sharply in March 2024 with a spike to 74,001 million USD. Following this increase, debt levels remained elevated, fluctuating between 67,144 million USD and 72,858 million USD through March 2026.
Total Capital Erosion
Total capital showed a general downward trend over the analyzed timeframe. From an initial 89,757 million USD in March 2022, capital declined to 69,745 million USD by December 2023. Despite a temporary increase to 82,008 million USD in March 2024, a sustained decline followed, resulting in a closing value of 66,202 million USD in March 2026. The divergence between stable or increasing debt and decreasing total capital is the primary driver of the deteriorating solvency ratio.
Solvency Implications
The progression of the debt to capital ratio above 1.00 suggests a fundamental change in the balance sheet composition, typically indicative of negative shareholders' equity. The increase from a ratio of 0.82 in early 2022 to 1.10 by early 2026 reflects an increased reliance on borrowed funds and a reduction in the equity cushion available to creditors.

Debt to Assets

AbbVie Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings
Current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The solvency profile exhibits a cyclical pattern characterized by an initial period of deleveraging followed by a strategic increase in leverage and a subsequent phase of relative stabilization.

Initial Deleveraging Phase (March 2022 – December 2023)
A consistent downward trend in the debt-to-assets ratio is observed, decreasing from 0.51 to a low of 0.44. This period is marked by a steady reduction in total debt, which fell from 73,474 million USD to 59,385 million USD, while total assets experienced a more moderate decline from 143,211 million USD to 134,711 million USD.
Capital Structure Adjustment (March 2024)
A significant shift occurs in the first quarter of 2024, where total debt increases sharply to 74,001 million USD. This increase coincided with a peak in total assets at 148,874 million USD, resulting in the debt-to-assets ratio resetting to 0.50.
Stabilization and Recent Trajectory (June 2024 – March 2026)
The leverage ratio remained remarkably stable between 0.50 and 0.51 for the majority of 2024 and 2025. However, a final upward movement is noted by March 31, 2026, with the ratio reaching 0.53, driven by an increase in total debt to 72,858 million USD against total assets of 136,463 million USD.

Financial Leverage

AbbVie Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Total assets
Stockholders’ equity (deficit)
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= ÷ =

2 Click competitor name to see calculations.


The analysis of the solvency indicators reveals a period of significant financial structural transformation, characterized by a steady erosion of stockholders' equity and a resulting exponential increase in financial leverage. While total assets remained relatively stable throughout the observed period, the precipitous decline in equity has shifted the balance sheet from a positive equity position to a substantial deficit.

Stockholders' Equity Trend
A consistent downward trajectory is observed in stockholders' equity, falling from 16,283 million USD in March 2022 to 10,360 million USD by December 2023. This decline accelerated throughout 2024, dropping to 3,325 million USD by year-end. The trend culminated in a transition to negative equity starting in June 2025, reaching a deficit of 6,656 million USD by March 2026.
Total Asset Stability
Total assets exhibited low volatility, generally fluctuating between 133,898 million USD and 148,874 million USD. A temporary peak occurred in March 2024, followed by a gradual return to levels consistent with the 2022-2023 period. The stability of the asset base contrasts sharply with the volatility and decline of the equity component.
Financial Leverage Dynamics
The financial leverage ratio experienced an aggressive escalation. In 2022, the ratio remained relatively stable, oscillating between 8.04 and 9.77. Starting in 2023, a clear upward trend emerged, with the ratio rising to 13.00 by December 2023. The acceleration intensified in 2024, climbing from 18.59 in March to 40.65 by December. By March 2025, the leverage ratio reached a peak of 95.89, reflecting the extreme narrowing of the equity base relative to total assets.

The convergence of stable assets and diminishing equity indicates a strategy or financial condition where liabilities have expanded to encompass the entirety of the asset base and beyond. The shift into a negative equity position by mid-2025 signifies that total liabilities have exceeded total assets, rendering traditional leverage ratios mathematically extreme or non-applicable as the equity base vanished.